PF-Atlas › Clinical Trials › NCT01082367

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

TOBI · Phase 3

Registry ID

NCT01082367

Phase

Phase 3

Status

Completed

Drug / intervention

TOBI

Sponsor

Novartis Pharmaceuticals

Start

2010-04

About this trial

TOBI is evaluated in NCT01082367, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Novartis Pharmaceuticals. Current status: Completed.

View NCT01082367 on ClinicalTrials.gov →

Explore related

All TOBI trials All IPF trials

Related trials

TOBI — NCT02212587

Medical disclaimer. This page summarizes public trial data for NCT01082367 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.